The global
oropharyngeal cancer therapeutics market is expected to have
significant growth since the pipeline for oropharyngeal cancer is growing
rapidly.
Also, there
are no specific drugs available for the treatment of oropharyngeal cancer
providing increased opportunities for the major key players.
Oral cavity
tumor or oral tumor, is tumor that begins in the mouth (also known as the oral
cavity). Oropharyngeal malignancy begins in the oropharynx, which is the part
of the throat behind the mouth. The oral cavity comprises of lips, the inside
lining of the lips and cheeks (buccal mucosa), the teeth, the gums, the front
two-thirds of the tongue, the floor of the mouth below the tongue and the bony
roof of the mouth (hard palate). The area behind the wisdom teeth, called the
retromolar trigone is also sometimes included in the oral cavity, though it is
often considered part of the oropharynx.
Request to Get the
Sample Pages at:
The
oropharynx is the part of the throat just behind the mouth and begins where the
oral cavity stops. It comprises of base of the tongue (the back third of the
tongue), the soft palate (the back part of the roof of the mouth), the tonsils,
and the side and back wall of the throat.
Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=oropharyngeal-cancer-therapeutics-market
The
oropharyngeal cancer therapeutics market is segmented based on the therapy
which includes surgery, chemotherapy, radiation therapy, targeted therapy and
palliative treatment. Chemotherapy holds the largest share since it contains
maximum number of drugs including, Cisplatin, Carboplatin, 5-fluorouracil
(5-FU), Paclitaxel (Taxol) and Docetaxel (Taxotere). The palliative treatment
segment holds the second largest share including, ibuprofen, acetaminophen,
morphine or similar drugs. Targeted therapy holds the lowest share and includes
only one drug, Cetuximab which may be combined with radiation therapy.
Some of the
key players operating in the oropharyngeal cancer therapeutics market include
Genticel S.A., AstraZeneca Plc, Kolltan Pharmaceuticals Inc., PNP Therapeutics
Inc., Novartis AG, Advaxis Inc., Merck & Co. Inc., VLPbio and Synta Pharmaceuticals
Corp.
